Novavax reported $162.58M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Adma Biologics USD 225.36M 6.93M Jun/2026
Agenus USD 38.52M 3.2M Mar/2026
AstraZeneca USD 1.55B 28K Sep/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
Cassava Sciences USD 48.31M 0 Jun/2026
Geron USD 640.9M 2.54M Mar/2026
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
MannKind USD 321.63M 11.72M Sep/2026
Merck USD 2.47B 1.05M Jun/2026
Minerva Neurosciences USD 1000 0 Sep/2024
Moderna USD 391M 2M Sep/2025
Novartis USD 1.89B 19.47M Sep/2026
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 0 Jun/2026
Sanofi EUR 1.2B 0 Sep/2026
Sarepta Therapeutics USD 107.23M 1.61M Sep/2026
TG Therapeutics USD 153.08M 2.23M Jun/2026